In colorectal and breast cancers, we use proteomics to identify a senescence secretome to find biomarkers that could predict the efficacy of treatments.
The TripleTOF® 5600+ System, a robust LC-MS/MS platform working at high throughput in microflow mode. It’s way faster – 1 hour per sample - and more robust compared to nano flow with similar sensitivity.
We use SWATH Acquisition to get comprehensive coverage and high quality quantitation across many samples.
We can work on very large cohorts (more than 150 tumor samples) to identify robust biomarkers or to better understand the cancer biology.